Renal Cell Carcinoma | Clinical

Overall Survival Results of I/O Combinations Differ Across Risk Groups of Metastatic RCC

July 22, 2021

The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.

ARO-HIF2 Shows Signals of Activity, Safety in Clear Cell Renal Cell Carcinoma

July 08, 2021

ARO-HIF2, an investigational tumor-targeting medicine utilizing the Targeted RNAi molecule platform from Arrowhead Pharmaceuticals, Inc., may be a safe and effective treatment for patients with clear cell renal cell carcinoma.

Follow-Up Shows Continued Efficacy in RCC With Pembrolizumab/Axitinib

July 07, 2021

Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.